DSIP — 5 mg

Delta sleep-inducing peptide is a nine-residue peptide historically associated with slow-wave sleep research. Umbrella Labs describes its initial isolation from rabbit blood and notes that its natural physiological role remains uncertain. The seller connects it with sleep, withdrawal, stress-hormone and temperature research rather than presenting a fully defined receptor mechanism. Consequently, its name reflects the experimental history of the molecule, not a complete explanation of how human sleep is controlled.

The human literature illustrates the range of claims surrounding DSIP. An early study in six middle-aged people with chronic insomnia described a normalizing effect on disturbed sleep. A later double-blind study in sixteen patients found better sleep efficiency and shorter sleep latency on selected objective measures, but the authors judged these differences weak and found no improvement in subjective sleep quality. They concluded that the short-term intervention was unlikely to provide major therapeutic benefit. Read together, the papers explain why DSIP descriptions emphasize sleep regulation while also reporting inconsistent results. The relevant distinction is between measured sleep-laboratory outcomes and broader promotional language about restorative sleep or stress recovery.